Early- and Delayed Antipsychotic Response and Prediction of Outcome in 528 Severely Impaired Patients with Schizophrenia Treated with Amisulpride

Lambert, Martin; Schimmelmann, Benno Karl Edgar; Naber, Dieter; Eich, F.X.; Schulz, Hartmut; Huber, Christian G.; Karow, Anne

doi:10.1055/s-0029-1234105

Cited by 42 publications

(40 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improvements in quality of life (QoL) are known to represent relevant predictors for symptomatic remission and functional recovery and have therefore become an increasingly important objective in the treatment of schizophrenia . Past studies have shown that the major factors influencing QoL in patients with schizophrenia include symptom severity, level of psychosocial functioning, and the presence of medication side‐effects .…”

Section: Introductionmentioning

confidence: 99%

Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and self‐esteem

Wartelsteiner

Mizuno

Frajo-Apor

et al. 2016

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and self‐esteem

Wartelsteiner

Mizuno

Frajo-Apor

et al. 2016

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…Social functioning may, therefore, represent an area that requires treatment beyond the resolution of overt symptoms of psychosis [32]. Conversely, early improvements in social functioning [33] or subjective well-being may be predictors of symptomatic remission [34] and of a good overall treatment outcome, supporting the importance of assessing social functioning in patients with schizophrenia [33]. Methods of gathering information in order to assess functioning are, however, known to vary and can include the perceptions or ratings of health care professionals, patients and family members [10,35].…”

Section: Introductionmentioning

confidence: 99%

Psychiatrists’ perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa

et al. 2013

View full text Add to dashboard Cite

BackgroundIt has been estimated that as many as two thirds of patients with schizophrenia are unable to perform basic personal and social roles or activities. Occupational functioning and social functioning, as well as independent living, are considered as core domains of patient functioning. Improvement in patient functioning has also been recognized as an important treatment goal in guidelines and an important outcome by regulatory agencies. Nevertheless, information is lacking on how these aspects are being considered by psychiatrists across the world and how they are being assessed and managed.MethodsThe ‘Europe, the Middle East and Africa functioning survey’ was designed to canvas opinions of psychiatrists across these regions to ascertain their perceptions of the clinical importance, assessment and management of functioning amongst their patients with schizophrenia. The survey comprised 17 questions and was conducted from March to April 2011 in 42 countries. Data collected included the demographics of respondents and their opinions regarding personal and social functioning in patients with schizophrenia.ResultsResults were obtained from 4,163 clinicians. Psychiatrists estimated that more than two thirds (70%) of their patients with schizophrenia showed impaired or very poor levels of functioning. The majority of psychiatrists (92%) believed that personal and social functioning was an important treatment goal for patients with schizophrenia, and 91% believed it was an important goal for patients’ families. The majority of psychiatrists (55%) assess the personal and social functioning of their patient at each visit; however, 81% reported that they determine the level of functioning through clinical interview and not by using a specific assessment scale. To manage personal and social functioning in their patients, 26% of psychiatrists prefer pharmacological interventions, whereas 46% prefer psychosocial interventions.ConclusionPsychiatrists recognize that functioning is impaired/very poor in patients with schizophrenia, and there is still an important need to address functioning as a main treatment goal for patients with schizophrenia.

show abstract

“…However, we found that while the prediction from the early response at 2 weeks was applicable to risperidone, it was not necessarily applicable to olanzapine . Subsequent studies confirmed these results, with two studies reporting that predictions of the later response could be made based on the response at 3 but not 2 weeks, while three studies reported being able to predict the later response at 4 weeks . One other study, however, reported that predictions could not be made before 6 weeks .…”

Section: How Does Practical Pharmacotherapy For Acute Schizophrenia Pmentioning

confidence: 69%

“…Out of the remaining 21, there were two articles that were not associated with response prediction from early responses, and one that was a duplicate of a previous article. After the discovery of one additional suitable article, a total of 19 articles were included in our review (Table ) …”

Section: How Does Practical Pharmacotherapy For Acute Schizophrenia Pmentioning

confidence: 99%

Practical pharmacotherapy for acute schizophrenia patients

Hatta

2015

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Well-organized clinical guidelines of pharmacotherapy for schizophrenia are not necessarily applicable to emergency and acute-phase situations. Thus, practical pharmacotherapy for acute schizophrenia patients should be based on data from real clinical practice and be independent of pharmaceutical companies. This study investigated the current guidelines being used to determine the initially preferred antipsychotics, durations required before an antipsychotic is viewed as being ineffective, and the strategies utilized for early non-responders that include switching, high dose, and augmentation. In patients who develop side-effects to the preferred antipsychotic drug, continued use may depend on the specific characteristics of the side-effects. For acute-phase patients, antipsychotics with high efficacy and effectiveness may be chosen based on meta-analysis findings for not only double-blinded but also raterblinded randomized controlled trials. Many previous studies have reported being able to make an early prediction at 2 weeks regarding the later response. These predictions were supported by the findings of a recent meta-analysis of 34 studies that examined 9975 participants. In early non-responders to the initial antipsychotic, the effectiveness of the switching strategy appears to depend on the initial antipsychotic administered and the antipsychotic the patient is subsequently switched to. Furthermore, the effectiveness of the strategy between switching and augmentation might also depend on the initial antipsychotic administered. The current findings might serve as the basis for the use of dosing above the licensed range versus continuing the use of conventional dosing in non-responders, provided there is close monitoring of the side-effects. Further research is required before any modifications of routine practices are undertaken regarding the direction of new potential treatments.

show abstract

Early- and Delayed Antipsychotic Response and Prediction of Outcome in 528 Severely Impaired Patients with Schizophrenia Treated with Amisulpride

Cited by 42 publications

References 28 publications

Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and self‐esteem

Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and self‐esteem

Psychiatrists’ perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa

Practical pharmacotherapy for acute schizophrenia patients

Contact Info

Product

Resources

About